Search

Displaying results 5911 - 5920 of 10000 in total
  1. Drug

    Pinolcaine

    go.drugbank.com/drugs/DB21159
    Experimental

    Pinolcaine is a small molecule drug. The usage of the INN stem '-caine' in the name indicates that Pinolcaine is a local anaesthetic. Pinolcaine has a monoisotopic molecular weight of 351.22 Da.

  2. Drug

    Lorcinadol

    go.drugbank.com/drugs/DB21160
    Experimental

    Lorcinadol is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Lorcinadol is a analgesic. Lorcinadol has a monoisotopic molecular weight of 314.13 Da.

  3. Drug

    Linarotene

    go.drugbank.com/drugs/DB21165
    Experimental

    Linarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Linarotene is a arotinoid derivative. Linarotene has a monoisotopic molecular weight of 398.2 Da.

  4. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary

  5. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  6. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours.

  7. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.

  8. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  9. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  10. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.